GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » International Stem Cell Corp (OTCPK:ISCO) » Definitions » Price-to-Owner-Earnings

International Stem Cell (International Stem Cell) Price-to-Owner-Earnings : (As of Jun. 08, 2024)


View and export this data going back to 2006. Start your Free Trial

What is International Stem Cell Price-to-Owner-Earnings?

As of today (2024-06-08), International Stem Cell's share price is $0.08985. International Stem Cell does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for International Stem Cell's Price-to-Owner-Earnings or its related term are showing as below:

During the past 13 years, the highest Price-to-Owner-Earnings of International Stem Cell was 0.71. The lowest was 0.46. And the median was 0.69.


ISCO's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.7
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-08), International Stem Cell's share price is $0.08985. International Stem Cell's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.06. Therefore, International Stem Cell's PE Ratio for today is At Loss.

As of today (2024-06-08), International Stem Cell's share price is $0.08985. International Stem Cell's EPS without NRI for the trailing twelve months (TTM) ended in was $-0.06. Therefore, International Stem Cell's PE Ratio without NRI for today is At Loss.

During the past 13 years, International Stem Cell's highest PE Ratio without NRI was 24.00. The lowest was 0.00. And the median was 18.67.


International Stem Cell Price-to-Owner-Earnings Historical Data

The historical data trend for International Stem Cell's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

International Stem Cell Price-to-Owner-Earnings Chart

International Stem Cell Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

International Stem Cell Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of International Stem Cell's Price-to-Owner-Earnings

For the Biotechnology subindustry, International Stem Cell's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


International Stem Cell's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, International Stem Cell's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where International Stem Cell's Price-to-Owner-Earnings falls into.



International Stem Cell Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

International Stem Cell's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.08985/-0.05
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


International Stem Cell  (OTCPK:ISCO) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


International Stem Cell Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of International Stem Cell's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


International Stem Cell (International Stem Cell) Business Description

Traded in Other Exchanges
N/A
Address
9745 Businesspark Avenue, San Diego, CA, USA, 92131
International Stem Cell Corp is a clinical-stage biotechnology company. It is focused on therapeutic and biomedical product development with multiple long-term therapeutic opportunities. The company develops different cell types from its stem cells that may result in therapeutic products. The clinical applications of the company include neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; Liver cells, which are used to treat a variety of congenital and acquired liver diseases; and retinal cells and three-dimensional eye structures. It operates in three segments, the therapeutic market, the biomedical market, and the anti-aging market. The Biomedical products business segment accounts for the majority of revenue.
Executives
Paul V Maier director 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Andrei Semechkin 10 percent owner 1 OVERLOOK DR. UNIT 11, AMHERST NH 03031
Sofya Bakalova officer: Dir. of Legal Affairs & Oper. 5950 PRIESTLY DRIVE, CARLSBAD CA 92008
Wright Don director 2829 RUCKER AVE, 3RD FLOOR, EVERETT WA 98201
Jennifer Stephens officer: Acting Chief Financial Officer 5950 PRIESTLY DRIVE, CARLSBAD CA 92008
Mahnaz Ebrahimi officer: Chief Financial Officer 5950 PRIESTLY DRIVE, CARLSBAD CA 92008
Rouslan Semechkin director, 10 percent owner 2595 JASON CT, OCEANSIDE CA 92056
Tibor Jay Novak officer: Interim CFO 5950 PRIESTLY DRIVE, CARLSBAD CA 92008
John Simon Craw officer: Executive Vice President 5950 PRIESTLY DRIVE, CARLSBAD CA 92008
James H Berglund director C/O INTERNATIONAL STEM CELL CORPORATION, 5950 PRIESTLY DRIVE, CARLSBAD CA 92008
Ar Partners Llc 10 percent owner 5950 PRIESTLY DR., CARLSBAD CA 92008
Kurt Andrew May officer: President and COO 5950 PRIESTLY DRIVE, CARLSBAD CA 92008
Linh T Nguyen officer: Chief Financial Officer 5950 PRIESTLY DR., CARLSBAD CA 92008
Jeffrey Janus director, officer: President 2595 JASON COURT, OCEANSIDE CA 92056
Charles J Casamento director 99 BELBROOK WAY, ATHERTON CA 94027